Prucalopride Versus Placebo in Gastroparesis

Summary

Controlled cross-over study of prucalopride 2 mg daily or placebo in gastroparesis (idiopathic or diabetic). Patients will be randomized to 4 week treatment with the first regimen (double-blind), followed by a 2-week washout and 4 week treatment with the second regimen in cross-over.

Timeline

Start

2011-11

Primary completion

2021-01-08

Completion

2021-01-08

Drugs

Indications